SVRA
Savara Inc.6.43
-0.18-2.72%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.31BP/E (TTM)
-Basic EPS (TTM)
-0.53Dividend Yield
0%Recent Filings
10-Q
8-K
Savara prices $130M offering
Savara Inc. priced a $130.0 million public offering of 23,809,524 common shares at $4.20 each and pre-funded warrants for 7,142,857 shares at $4.199, with underwriters holding a 30-day option for 4,642,857 more shares. The deal closes October 31, 2025, funding MOLBREEVI's clinical development, regulatory pursuit, and commercialization prep for autoimmune PAP. Proceeds bolster Savara's rare disease pipeline. Yet closing hinges on customary conditions.
8-K
Savara updates MOLBREEVI Phase 3 data
Savara Inc. updated its corporate presentation on September 2, 2025, highlighting positive Phase 3 IMPALA-2 results for MOLBREEVI in autoimmune PAP, showing statistically significant improvements in lung function (DLCO up 9.8% at week 24 vs. 3.8% placebo) and quality of life (SGRQ score down 11.5 vs. 4.9). The drug proved well-tolerated with low discontinuations, paving the way for a BLA resubmission in December 2025. MOLBREEVI targets a U.S. market of ~5,500 patients, larger than prior estimates. Savara's cash lasts into Q1 2027.
10-Q
Q2 FY2025 results
Savara Inc. ramped up spending in Q2 FY2025 ended June 30, 2025, with operating expenses climbing 35.6% y/y to $31.4M on higher R&D ($20.8M, up 17.8% y/y) and G&A ($10.7M, up 92.3% y/y), driving a net loss of $30.4M or $0.14 per diluted share—wider than the $22.2M or $0.12 loss last year, reconciled against 216M weighted shares with anti-dilutive effects from options and warrants. YTD through June, the net loss hit $57.0M or $0.26 per share, up from $42.6M or $0.23, fueled by MOLBREEVI program advances including CMC and regulatory efforts, while clinical costs dipped slightly. Cash burn from operations totaled $53.5M YTD, offset by $53.7M in investing inflows; quarter-end liquidity stood strong at $146.4M in cash and short-term investments, backed by $29.7M in long-term debt under the new Hercules facility (prime +1.45%, maturing 2030) that refinanced prior obligations with a $0.5M extinguishment loss. No non-GAAP metrics disclosed in the 10-Q. Regulatory hurdles persist with the FDA's RTF on the BLA resubmission slated for December 2025.
8-K
Savara elects directors, ratifies auditors
Savara Inc. stockholders at the June 5, 2025 annual meeting elected six directors—Matthew Pauls, Nevan Elam, Richard J. Hawkins, Joseph S. McCracken, David A. Ramsay, and An van Es-Johansson—each securing over 118 million votes for, despite some opposition. They ratified RSM US LLP as auditors for 2025 with 151 million for votes and approved executive compensation advisory, favoring annual say-on-pay votes by 123 million. Board continuity holds firm. No major disruptions noted.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ATRA
Atara Biotherapeutics, Inc.
17.58-0.37
BCAX
Bicara Therapeutics Inc.
18.15-0.21
IVA
Inventiva S.A. - American Depos
4.66+0.18
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SAVA
Cassava Sciences, Inc.
2.93+0.13
TARA
Protara Therapeutics, Inc.
5.42-0.08
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02